Page last updated: 2024-12-08

dizocilpine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID180081
CHEMBL ID284237
CHEBI ID132408
CHEBI ID34725
SCHEMBL ID34528
MeSH IDM0329461

Synonyms (95)

Synonym
bdbm50030386
1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10(15),11,13-hexaene maleate((+)-mk801)
(1s)-1-methyl-16-azatetracyclo[7.6.1.0^{2,7}.0^{10,15}]hexadeca-2(7),3,5,10,12,14-hexaene; (2z)-but-2-enedioate
HMS3267C15
BRD-K58930050-001-01-1
BRD-K58930050-050-03-4
gtpl2403
5h-dibenzo(a,d)cyclohepten-5,10-imine, 10,11-dihydro-5-methyl-, (5s)-
dizocilpina [inn-spanish]
dizocilpine [inn]
dizocilpinum [inn-latin]
PRESTWICK2_000109
lopac-m-107
NCGC00015627-02
lopac-m-108
NCGC00015627-01
BSPBIO_000098
mk 801
mk-801
5h-dibenzo[a,d]cyclohepten-5,10-imine, 10,11-dihydro-5-methyl-, (5s)-, (2z)-2-butenedioate (1:1)
LOPAC0_000872
PDSP1_000178
BIOMOL-NT_000210
BPBIO1_000108
PDSP1_001281
BPBIO1_001272
PDSP2_000177
PDSP2_001265
dizocilpine ,
77086-21-6
mk801
PRESTWICK0_000109 ,
SPBIO_002037
PRESTWICK1_000109
PRESTWICK3_000109
NCGC00024876-02
CHEBI:132408 ,
NCGC00016935-06
chebi:34725 ,
CHEMBL284237 ,
(1s,9r)-1-methyl-16-azatetracyclo[7.6.1.0^{2,7}.0^{10,15}]hexadeca-2(7),3,5,10(15),11,13-hexaene
10,11-dihydro-5-methyl-5h-dibenzo[a,d]cyclohepten-5,10-imine.(mk-801)
(-)-1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10(15),11,13-hexaene
(dizocilpine)1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10(15),11,13-hexaene
1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10,12,14-hexaene
(5s,10s)-(+)-5-methyl-10,11-dihydro-5hdibenzo[a,d]cyclohepten-5,10-imine
mk-801 (dizocilpine)
(+)mk-801
(5s,10r)-(+)-5-methyl-10,11-dihydro-5hdibenzo[a,d]cyclohepten-5,10-imine
(+)-1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10(15),11,13-hexaene
(+/-)-mk801
1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2,4,6,10(15),11,13-hexaene
(+/-) mk-8011-methyl-(9r,1r)-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10(15),11,13-hexaene
(+)-mk-801
(-)-mk801
(1s,9r)-1-methyl-16-azatetracyclo[7.6.1.0^{2,7}.0^{10,15}]hexadeca-2,4,6,10(15),11,13-hexaene
(mk-801)1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10(15),11,13-hexaene
(+/-)-1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10(15),11,13-hexaene
1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10(15),11,13-hexaene(mk-801)
1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10(15),11,13-hexaene
bdbm50344263
CCG-204954
unii-7py8kh681i
hsdb 7641
dizocilpina
dizocilpinum
7py8kh681i ,
NCGC00016935-04
NCGC00016935-05
LBOJYSIDWZQNJS-CVEARBPZSA-N
SCHEMBL34528
dizocilpine [mi]
5h-dibenzo(a,d)cyclohepten-5,10-imine, 10,11-dihydro-5-methyl-, (+)-
dizocilpine [hsdb]
dizocilpine [who-dd]
(+)-10,11-dihydro-5-methyl-5h-dibenzo(a,d)cyclohepten-5,10-imine
DTXSID3048447
5h-dibenzo[a,d]cyclohepten-5,10-imine, 10,11-dihydro-5-methyl-, (5s,10r)-
AC-35306
AKOS026673945
(5s,10r)-5-methyl-10,11-dihydro-5h-5,10-epiminodibenzo[a,d][7]annulene
SW197022-4
Q4386371
EX-A1701
HY-15084B
CS-0020032
(rac)-dizocilpine
(rac)-mk-801
SDCCGSBI-0050847.P002
NCGC00016935-19
dizocilpine-(+)
AT27821
(1s,9r)-1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2,4,6,10,12,14-hexaene
CDA08621
(1s,9r)-1-methyl-16-azatetracyclo[7.6.1.0?,?.0??,??]hexadeca-2,4,6,10,12,14-hexaene

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" This efficient route enabled to scale up the synthesis of an orally bioavailable glycine antagonist showing outstanding in vivo anti-hyperalgesic activity in different animal models of sustained inflammation and chronic neuropathic pain."( Chiral tetrahydroquinoline derivatives as potent anti-hyperalgesic agents in animal models of sustained inflammation and chronic neuropathic pain.
Alvaro, G; Barnaby, RJ; Bertani, B; Corsi, M; Di Fabio, R; Donati, D; Gentile, G; Giacobbe, S; Pentassuglia, G; Pizzi, DM; Quartaroli, M; Ratti, E; Spada, S; Vitulli, G, 2007
)
0.34
" A pharmacokinetic study showed that they have good oral bioavailability in rats."( Synthesis and pharmacological profile of serofendic acids A and B.
Akaike, A; Asai, N; Doko, T; Kajiwara, A; Kimura, T; Kume, T; Niidome, T; Sakurai, H; Sugimoto, H; Taguchi, R; Takenaka, O; Terauchi, T; Yonaga, M, 2007
)
0.34
" N-(1-adamantyl)-2-oxo-chromene-3-carboxamide (8), N-adamantan-1-yl-5-dimethyl-amino-1-naphthalenesulfonic acid (11) and N-(1-cyano-2H-isoindol-2-yl) adamantan-1-amine (12) were found to possess a high degree of multifunctionality with favourable physical-chemical properties for bioavailability and blood-brain barrier permeability."( Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
Green, IR; Joubert, J; Malan, SF; van Dyk, S, 2011
)
0.37
", ip) indicate that the liver is the primary site of biotransformation of the compound, suggesting that both 22a and its metabolite(s) are active, compensating probably low bioavailability of the parent molecule."( Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E, 2016
)
0.43
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
" Additionally, an ∼85% correlation was obtained between PAMPA pH 5 permeability and in vivo oral bioavailability in mice and rats."( Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
Itkin, M; Kabir, M; Mathé, EA; Nguyễn, ÐT; Padilha, EC; Shah, P; Shinn, P; Siramshetty, V; Wang, AQ; Williams, J; Xu, X; Yu, KR; Zhao, T, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
NMDA receptor antagonistAny substance that inhibits the action of N-methyl-D-aspartate (NMDA) receptors. They tend to induce a state known as dissociative anesthesia, marked by catalepsy, amnesia, and analgesia, while side effects can include hallucinations, nightmares, and confusion. Due to their psychotomimetic effects, many NMDA receptor antagonists are used as recreational drugs.
anaestheticSubstance which produces loss of feeling or sensation.
anticonvulsantA drug used to prevent seizures or reduce their severity.
nicotinic antagonistAn antagonist at the nicotinic cholinergic receptor.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
tetracyclic antidepressantAn antidepressant whose molecular structure consists of four ring-like structures in a T-shape.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (54)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency0.00500.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency0.00500.025120.237639.8107AID886
thioredoxin reductaseRattus norvegicus (Norway rat)Potency5.97280.100020.879379.4328AID488773; AID588453
NFKB1 protein, partialHomo sapiens (human)Potency10.00000.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency0.63100.35487.935539.8107AID624146
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency5.62340.035520.977089.1251AID504332
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency8.91251.000012.232631.6228AID1452
chromobox protein homolog 1Homo sapiens (human)Potency0.00750.006026.168889.1251AID488953
mitogen-activated protein kinase 1Homo sapiens (human)Potency0.00200.039816.784239.8107AID995
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency20.48390.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.19950.00106.000935.4813AID943
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency20.48391.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency9.52830.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID71569
Glutamate receptor ionotropic, NMDA 2DHomo sapiens (human)Ki0.00400.00120.70256.0000AID156805
Glutamate receptor ionotropic, NMDA 3BHomo sapiens (human)Ki0.00400.00120.70256.0000AID156805
CholinesteraseHomo sapiens (human)IC50 (µMol)16.00000.00001.559910.0000AID1729625
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Ki100.00000.00010.579710.0000AID140979
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)Ki100.00000.00011.48339.1400AID140979
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)Ki100.00000.00010.68688.2600AID140979
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)Ki100.00000.00010.66618.2600AID140979
Muscarinic acetylcholine receptor M5Homo sapiens (human)IC50 (µMol)0.00200.00010.99178.0000AID255298
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)Ki100.00000.00010.58908.2600AID140979
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID71569
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID71569
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Ki100.00000.00020.561410.0000AID71569
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Ki100.00000.00020.635210.0000AID71569
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki100.00000.00020.621710.0000AID71569
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Ki100.00000.00020.675810.0000AID71569
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki70.43350.00020.646910.0000AID71569; AID71570
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID71569
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID71569
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Ki100.00000.00020.671210.0000AID71569
Mu-type opioid receptorRattus norvegicus (Norway rat)Ki100.00000.00000.38458.6000AID224709
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)0.01490.00071.600310.0000AID144471; AID144969; AID144970; AID144979; AID145040; AID225475
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Ki0.03920.00030.86666.6900AID142990; AID145236; AID145237; AID145318; AID145319
Lysosomal Pro-X carboxypeptidaseHomo sapiens (human)IC50 (µMol)0.00530.00530.60331.9000AID157589
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Ki100.00000.00020.557710.0000AID71569
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Ki100.00000.00020.640310.0000AID71569
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Ki100.00000.00020.570810.0000AID71569
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)0.01490.00071.630610.0000AID144471; AID144969; AID144970; AID144979; AID145040; AID225475
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)Ki0.03920.00030.68056.6900AID142990; AID145236; AID145237; AID145318; AID145319
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)0.01490.00061.525710.0000AID144471; AID144969; AID144970; AID144979; AID145040; AID225475
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)Ki0.03920.00030.70716.6900AID142990; AID145236; AID145237; AID145318; AID145319
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)0.01490.00071.747210.0000AID144471; AID144969; AID144970; AID144979; AID145040; AID225475
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)Ki0.03920.00030.81966.6900AID142990; AID145236; AID145237; AID145318; AID145319
Glutamate receptor ionotropic, NMDA 1Homo sapiens (human)IC50 (µMol)0.00900.00101.88779.8000AID339209
Glutamate receptor ionotropic, NMDA 1Homo sapiens (human)Ki0.00400.00120.48246.0000AID156805
Glutamate receptor ionotropic, NMDA 2AHomo sapiens (human)IC50 (µMol)0.02900.00101.99589.8000AID598086
Glutamate receptor ionotropic, NMDA 2AHomo sapiens (human)Ki0.00400.00120.62056.0000AID156805
Glutamate receptor ionotropic, NMDA 2BHomo sapiens (human)IC50 (µMol)0.00900.00401.33259.8000AID339209
Glutamate receptor ionotropic, NMDA 2BHomo sapiens (human)Ki0.00400.00120.32686.0000AID156805
Glutamate receptor ionotropic, NMDA 2CHomo sapiens (human)Ki0.00400.00120.70256.0000AID156805
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)0.01490.00071.741110.0000AID144471; AID144969; AID144970; AID144979; AID145040; AID225475
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)Ki0.03920.00030.70726.6900AID142990; AID145236; AID145237; AID145318; AID145319
Glutamate receptor ionotropic, NMDA 3AHomo sapiens (human)Ki0.00400.00120.70256.0000AID156805
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)0.01490.00071.741110.0000AID144471; AID144969; AID144970; AID144979; AID145040; AID225475
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)Ki0.03920.00030.70726.6900AID142990; AID145236; AID145237; AID145318; AID145319
GABA theta subunitRattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID71569
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki59.16700.00000.490110.0000AID229181
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID71569
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)1.70000.00030.55704.2000AID204608
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)Ki59.16700.00030.26715.0700AID229181
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)0.01490.00071.741110.0000AID144471; AID144969; AID144970; AID144979; AID145040; AID225475
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)Ki0.03920.00030.70726.6900AID142990; AID145236; AID145237; AID145318; AID145319
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Kd0.03720.03725.018610.0000AID1265114
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)Kd0.03720.03725.018610.0000AID1265114
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)Kd0.03720.03725.018610.0000AID1265114
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)Kd0.03720.03725.018610.0000AID1265114
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)Kd0.03720.03725.018610.0000AID1265114
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)Kd0.03720.03725.018610.0000AID1265114
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)Kd0.03720.03725.018610.0000AID1265114
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Kb0.19330.00592.09697.0000AID145179
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)Kb0.19330.00592.41137.0000AID145179
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)Kb0.19330.00592.41137.0000AID145179
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)Kb0.19330.00592.41137.0000AID145179
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)Kb0.19330.00592.41137.0000AID145179
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)Kb0.19330.00592.41137.0000AID145179
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)Kb0.19330.00592.41137.0000AID145179
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (97)

Processvia Protein(s)Taxonomy
startle responseGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
adult locomotory behaviorGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of sensory perception of painGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
cellular response to L-glutamateGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
protein insertion into membraneGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
regulation of calcium ion transportGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
calcium ion transmembrane transportGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
gastric acid secretionMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
dopamine transportMuscarinic acetylcholine receptor M5Homo sapiens (human)
transmission of nerve impulseMuscarinic acetylcholine receptor M5Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylationMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M5Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
regulation of thyroid hormone mediated signaling pathwayLysosomal Pro-X carboxypeptidaseHomo sapiens (human)
plasma kallikrein-kinin cascadeLysosomal Pro-X carboxypeptidaseHomo sapiens (human)
proteolysisLysosomal Pro-X carboxypeptidaseHomo sapiens (human)
glucose homeostasisLysosomal Pro-X carboxypeptidaseHomo sapiens (human)
energy homeostasisLysosomal Pro-X carboxypeptidaseHomo sapiens (human)
regulation of reactive oxygen species metabolic processLysosomal Pro-X carboxypeptidaseHomo sapiens (human)
angiogenesis involved in wound healingLysosomal Pro-X carboxypeptidaseHomo sapiens (human)
negative regulation of systemic arterial blood pressureLysosomal Pro-X carboxypeptidaseHomo sapiens (human)
regulation of blood vessel endothelial cell migrationLysosomal Pro-X carboxypeptidaseHomo sapiens (human)
cellular response to amyloid-betaGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
monoatomic cation transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
visual learningGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of calcium ion transport into cytosolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
propylene metabolic processGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of membrane potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein heterotetramerizationGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion homeostasisGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of reactive oxygen species biosynthetic processGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
response to glycineGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
cellular response to amyloid-betaGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
startle responseGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to amphetamineGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
learning or memoryGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
memoryGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
visual learningGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to xenobiotic stimulusGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to woundingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
sensory perception of painGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
neurogenesisGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein catabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
sleepGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
directional locomotionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
negative regulation of protein catabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
dopamine metabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
serotonin metabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of apoptotic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
activation of cysteine-type endopeptidase activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein localization to postsynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
learning or memoryGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
protein heterotetramerizationGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
negative regulation of dendritic spine maintenanceGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
response to woundingGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
directional locomotionGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
negative regulation of protein catabolic processGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
neuromuscular process controlling balanceGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
protein localization to postsynaptic membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
calcium ion transportGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
dendrite developmentGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
rhythmic processGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
prepulse inhibitionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
negative regulation of dendritic spine developmentGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
calcium ion transmembrane transportGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
glutamate-gated receptor activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
voltage-gated monoatomic cation channel activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
calcium channel activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
monoatomic cation channel activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
neurotransmitter receptor activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
glutamate receptor activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
serine-type carboxypeptidase activityLysosomal Pro-X carboxypeptidaseHomo sapiens (human)
protein bindingLysosomal Pro-X carboxypeptidaseHomo sapiens (human)
dipeptidyl-peptidase activityLysosomal Pro-X carboxypeptidaseHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calmodulin bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein-containing complex bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
signaling receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
ligand-gated monoatomic ion channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
zinc ion bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
zinc ion bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
calcium channel activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
identical protein bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
protein phosphatase 2A bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
glutamate receptor activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (47)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
presynaptic active zone membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
hippocampal mossy fiber to CA3 synapseGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
neuronal cell bodyGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneLysosomal Pro-X carboxypeptidaseHomo sapiens (human)
azurophil granule membraneLysosomal Pro-X carboxypeptidaseHomo sapiens (human)
intracellular membrane-bounded organelleLysosomal Pro-X carboxypeptidaseHomo sapiens (human)
basal part of cellLysosomal Pro-X carboxypeptidaseHomo sapiens (human)
extracellular exosomeLysosomal Pro-X carboxypeptidaseHomo sapiens (human)
ficolin-1-rich granule membraneLysosomal Pro-X carboxypeptidaseHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
cytoplasmGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic vesicleGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
dendriteGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic cleftGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
terminal boutonGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
dendritic spineGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic vesicleGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cytoplasmic vesicle membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
presynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
dendritic spineGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cytoplasmGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
lysosomeGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
late endosomeGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
cytoskeletonGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
neuronal cell bodyGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
synapseGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
presynapseGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (183)

Assay IDTitleYearJournalArticle
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1645871NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling in pH 5 buffer2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1237859Displacement of [3H]-(+)-MK-801 from phencyclidine binding site of NMDA receptor in pig membranes after 150 mins by scintillation counting analysis2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Stereoselective synthesis and pharmacological evaluation of [4.3.3]propellan-8-amines as analogs of adamantanamines.
AID204616Inhibition of [3H]NANM binding to sigma receptor obtained from tissue homogenate preparation of fresh whole rat brain minus cerebellum1998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
Rigid phencyclidine analogues. Binding to the phencyclidine and sigma 1 receptors.
AID1415570Displacement of [3H]-di-o-tolylguanidine from sigma 2 receptor in rat liver membranes after 120 mins by scintillation counting analysis2017MedChemComm, May-01, Volume: 8, Issue:5
Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?
AID377488Antidepressant activity in CF1 mouse assessed as decrease in duration of immobility at 0.15 mg/kg during final 4 mins of the 6 mins session by forced swimming test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID88591In vitro neuroprotection against glutamate-induced toxicity at 5 uM using rat hippocampal cell cultures at 100 uM of glutamate1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
10,5-(Iminomethano)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene and derivatives. Potent PCP receptor ligands.
AID145319Binding affinity against phencyclidine (PCP) site of N-methyl-D-aspartate glutamate receptor from rat brain, using [3H]- TCP as radioligand.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Novel NMDA antagonists: replacement of the pyridinium ring of 6,11-ethanobenzo[b]quinolizinium cations with heteroisoquinolinium cations.
AID1191388Displacement of (+)-[3H]pentazocine from guinea pig brain cortex sigma1 receptor by scintillation analyzer2015European journal of medicinal chemistry, Jan-27, Volume: 90Improving selectivity preserving affinity: new piperidine-4-carboxamide derivatives as effective sigma-1-ligands.
AID353103Displacement of [3H]MK801 from NMDA receptor in rat brain neuronal membrane2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds.
AID145040The compound was tested in vitro for the inhibition of N-methyl-D-aspartate glutamate receptor in rat cerebellar granule cells (RCGCs).2000Bioorganic & medicinal chemistry letters, Nov-06, Volume: 10, Issue:21
Chiral synthesis and pharmacological evaluation of NPS 1407: a potent, stereoselective NMDA receptor antagonist.
AID1597396Displacement of [3H]-(+)-MK-801 from NMDA PCP binding site in pig brain cortex membrane at 1 uM incubated for 120 mins by scintillation counting method relative to control
AID305670Displacement of [3H]MK-801 from NMDA receptor in ICR mouse synaptoneurosome at 100 uM2007Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3
Structure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor.
AID145179Antagonistic activity against N-methyl-D-aspartate glutamate receptor from rat cortical slice1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and pharmacological evaluation of a series of dibenzo[a,d]cycloalkenimines as N-methyl-D-aspartate antagonists.
AID391345Effect on motor coordination in mouse at 0.3 mg/kg, ip administered 20 mins prior to test after 5 days by rotarod test2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists.
AID1672602Cytotoxicity against human SK-BR-3 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Role of the NMDA Receptor in the Antitumor Activity of Chiral 1,4-Dioxane Ligands in MCF-7 and SKBR3 Breast Cancer Cells.
AID139972Ratio of IC50 value for closed channel binding to that of open channel binding.1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Discovery of 6,11-ethano-12,12-diaryl-6,11-dihydrobenzo[b]quinolizinium cations, a novel class of N-methyl-D-aspartate antagonists.
AID127843Compound was evaluated in vivo for effective dose by subcutaneous administration in mice using cGMP assay1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Synthesis and biological activity of 8a-phenyldecahydroquinolines as probes of PCP's binding conformation. A new PCP-like compound with increased in vivo potency.
AID376761Neuroprotective effect against glutamate-stimulated rat cortical cells assessed as cell viability at 10 uM after 1 hr by LDH assay relative to control2005Journal of natural products, Jan, Volume: 68, Issue:1
Four new neuroprotective dihydropyranocoumarins from Angelica gigas.
AID139969NMDA antagonistic activity was evaluated in vivo in cultured mouse cortical neurons by patch clamp recordings designed to measure closed state binding to NMDA receptor-ionophore complex1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Discovery of 6,11-ethano-12,12-diaryl-6,11-dihydrobenzo[b]quinolizinium cations, a novel class of N-methyl-D-aspartate antagonists.
AID88592In vitro neuroprotection against glutamate-induced toxicity at 5 uM using rat hippocampal cell cultures at 1000 uM of glutamate1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
10,5-(Iminomethano)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene and derivatives. Potent PCP receptor ligands.
AID114644Compound was evaluated for in vivo activity assessed by prevention of NMDA-induced lethality in mice (N= 10 animals)1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
Synthesis and pharmacological evaluation of hexahydrofluorenamines as noncompetitive antagonists at the N-methyl-D-aspartate receptor.
AID88593In vitro neuroprotection against glutamate-induced toxicity at 5 uM using rat hippocampal cell cultures at 3 uM of glutamate1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
10,5-(Iminomethano)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene and derivatives. Potent PCP receptor ligands.
AID604208Antagonist activity at NMDAR in Sprague-Dawley rat brain synaptoneurosomes assessed as inhibition of NMDA/glycine-induced calcium flux at 100 uM after 5 mins using FURA-2AM by fluorescent spectrometer analysis relative to control2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
AID139970NMDA antagonistic activity was evaluated in vivo in cultured mouse cortical neurons by patch clamp recordings designed to measure open state binding to NMDA receptor-ionophore complex1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Discovery of 6,11-ethano-12,12-diaryl-6,11-dihydrobenzo[b]quinolizinium cations, a novel class of N-methyl-D-aspartate antagonists.
AID620267Antagonist activity at NMDA receptor in Sprague-Dawley rat striatal synaptoneurosomes assessed as inhibition of NMDA/glycine-induced calcium flux at 100 uM by spectrofluorimetric analysis relative to control2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis, evaluation and application of polycyclic fluorescent analogues as N-methyl-D-aspartate receptor and voltage gated calcium channel ligands.
AID309434Protective effect against glutamate-induced neurotoxicity in fetal rat cerebral cortex at 1 uM after 24 hrs2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Synthesis and pharmacological profile of serofendic acids A and B.
AID770306Cytotoxicity against Sprague-Dawley rat cortical neurons assessed as cell viability at 10 uM by LDH assay2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
Discovery of novel (1S)-(-)-verbenone derivatives with anti-oxidant and anti-ischemic effects.
AID604207Antagonist activity at VGCC in Sprague-Dawley rat brain synaptoneurosomes assessed as inhibition of Kcl-induced calcium flux at 100 uM after 5 mins using FURA-2AM by fluorescent spectrometer analysis relative to control2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
AID174031Reduction of photochemically induced cerebral focal ischemia in rat was evaluated by using control at 3 mg/kg intravenous dose1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis, resolution, and SAR of (+/-)-2-amino-N-methyl-alpha-(3-methyl-2-thienyl)benzeneethanamine++ + and related analogs as noncompetitive NMDA antagonists with neuroprotective properties.
AID1759915Toxicity in Wistar rat assessed as prepulse inhibition of acoustic startle response at 0.3 mg/kg, ip measured for 10 mins by open field test relative to control2021European journal of medicinal chemistry, Jul-05, Volume: 219Structure-activity relationships of dually-acting acetylcholinesterase inhibitors derived from tacrine on N-methyl-d-Aspartate receptors.
AID353104Ratio of Ki for rat brain NMDA receptor in presence of 100 uM spermine to Ki for rat brain NMDA receptor in absence of spermine2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds.
AID24432Partition coefficient was measured using a standard shake flask (SF) method at pH 7.4.1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
Synthesis and pharmacological evaluation of 4a-phenanthrenamine derivatives acting at the phencyclidine binding site of the N-methyl-D-aspartate receptor complex.
AID156807Ability to displace [3H]TCP from high affinity PCP N-methyl-D-aspartate glutamate receptor in rat brain homogenates in vitro was determined1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and structure-activity relationship of C5-substituted analogues of (+-)-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine [(+-)-desmethyl-MK801]: ligands for the NMDA receptor-coupled phencyclidine binding site.
AID1729625Inhibition of human BuChE using butyrylthiocholine iodide as substrate peincubated for 5 mins followed by substrate addition by DTNB-reagent based Ellman's method2021European journal of medicinal chemistry, Jan-15, Volume: 210Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT
AID346445Displacement of radiolabeled MK 801 from phencyclidine receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID26360pKa value was determined1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel benzo[b]quinolizinium cations as uncompetitive N-methyl-D-aspartic acid (NMDA) antagonists: the relationship between log D and agonist independent (closed) NMDA channel block.
AID191882Evaluated for reduction of NMDA-induced necrosis volume at 7.0 mg/kg intraperitoneally dose in rats.1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis, resolution, and SAR of (+/-)-2-amino-N-methyl-alpha-(3-methyl-2-thienyl)benzeneethanamine++ + and related analogs as noncompetitive NMDA antagonists with neuroprotective properties.
AID1129536Inhibition of glutamate-induced [45Ca2+] uptake in synaptosomes in rat brain cortex at 25 uM after 5 mins by scintillation counting relative to control2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis, biological activity, distribution and membrane permeability of novel spiro-thiazines as potent neuroprotectors.
AID191831Reduction of photochemically induced cerebral focal ischemia in rat was evaluated by using compound at 3 mg/kg intravenous dose1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis, resolution, and SAR of (+/-)-2-amino-N-methyl-alpha-(3-methyl-2-thienyl)benzeneethanamine++ + and related analogs as noncompetitive NMDA antagonists with neuroprotective properties.
AID143380Compound was evaluated for its affinity towards N-methyl-D-aspartate glutamate receptor in male Swiss Webster mice.1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Synthesis and biological activity of 8a-phenyldecahydroquinolines as probes of PCP's binding conformation. A new PCP-like compound with increased in vivo potency.
AID1692759Antagonist activity at NMDA receptor (unknown origin) assessed as trapping capability relative to control2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Repurposing of Drugs-The Ketamine Story.
AID1129534Inhibition of glutamate-induced [45Ca2+] uptake in synaptosomes in rat brain cortex at 100 uM after 5 mins by scintillation counting relative to control2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis, biological activity, distribution and membrane permeability of novel spiro-thiazines as potent neuroprotectors.
AID144035Binding affinity against dextromethorpin binding site associated with N-methyl-D-aspartate glutamate receptor from guinea pig mitochondrial pellet P2 determined at a concentration of 10e-5 M using [3H]1 as radioligand.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and evaluation of 3-substituted 17-methylmorphinan analogs as potential anticonvulsant agents.
AID391343Effect on locomotor activity in Sprague-Dawley rat at 0.3 mg/kg, ip2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists.
AID1336348Displacement of [3H]TCP from rat cerebral cortex phencyclidine receptor measured after 120 mins by scintillation counting method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
AID1191389Displacement of [3H]DTG from rat liver sigma2 receptor by scintillation analyzer2015European journal of medicinal chemistry, Jan-27, Volume: 90Improving selectivity preserving affinity: new piperidine-4-carboxamide derivatives as effective sigma-1-ligands.
AID131911Inhibition of N-Methyl-D,L-aspartate induced convulsions in mice following 500 mg/kg i.p.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and pharmacological evaluation of a series of dibenzo[a,d]cycloalkenimines as N-methyl-D-aspartate antagonists.
AID305671Displacement of [3H]TCP from NMDA receptor in ICR mouse synaptoneurosome at 100 uM2007Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3
Structure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor.
AID23268Partition coefficient determined using standard shake flask method at pH 7.4.1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
Synthesis and pharmacological evaluation of hexahydrofluorenamines as noncompetitive antagonists at the N-methyl-D-aspartate receptor.
AID298776Antinociceptive effect in mouse assessed as reduction of licking time in late phase administered at 0.1 mg/kg, ip before 10 mins of formalin administration2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
Chiral tetrahydroquinoline derivatives as potent anti-hyperalgesic agents in animal models of sustained inflammation and chronic neuropathic pain.
AID156806Evaluated for its affinity to bind PCP N-methyl-D-aspartate (NMDA) glutamate receptor in rat brain membrane using [3H]MK-801 as radioligand1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Role of hydrogen bonding in ligand interaction with the N-methyl-D-aspartate receptor ion channel.
AID88590In vitro neuroprotection against glutamate-induced toxicity at 5 uM using rat hippocampal cell cultures at 10 uM of glutamate1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
10,5-(Iminomethano)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene and derivatives. Potent PCP receptor ligands.
AID144183Agonistic activity at N-methyl-D-aspartate glutamate receptor was measured as [Ca2+] influx in rat cerebellar granule neurons at 1 uM concentration1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Synthesis and biology of the conformationally restricted ACPD analogue, 2-aminobicyclo[2.1.1]hexane-2,5-dicarboxylic acid-I, a potent mGluR agonist.
AID620265Antagonist activity at voltage gated calcium channel in Sprague-Dawley rat striatal synaptoneurosomes assessed as inhibition of KCl-induced calcium flux at 100 uM by spectrofluorimetric analysis relative to control2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis, evaluation and application of polycyclic fluorescent analogues as N-methyl-D-aspartate receptor and voltage gated calcium channel ligands.
AID391346Effect on motor coordination in mouse at 0.6 mg/kg, ip administered 20 mins prior to test after 5 days by rotarod test2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists.
AID144701Inhibitory activity against NMDA closed channel block1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel benzo[b]quinolizinium cations as uncompetitive N-methyl-D-aspartic acid (NMDA) antagonists: the relationship between log D and agonist independent (closed) NMDA channel block.
AID488105Displacement of [3H]-(+)-MK801 from PCP binding site of NMDA receptor from pig brain cortex after 150 mins by scintillation counting2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Synthesis and NMDA receptor affinity of fluorinated dioxadrol analogues.
AID144840Evaluated for their affinity at the PCP site for displacement of [3H]TCP in rat brain homogenates1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
Synthesis and pharmacological evaluation of hexahydrofluorenamines as noncompetitive antagonists at the N-methyl-D-aspartate receptor.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID156962Ratio of binding towards PCP receptor to that of sigma receptor1998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
Rigid phencyclidine analogues. Binding to the phencyclidine and sigma 1 receptors.
AID191880Evaluated for reduction of NMDA-induced necrosis volume at 2.0 mg/kg intraperitoneally dose in rats.1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis, resolution, and SAR of (+/-)-2-amino-N-methyl-alpha-(3-methyl-2-thienyl)benzeneethanamine++ + and related analogs as noncompetitive NMDA antagonists with neuroprotective properties.
AID1129540Inhibition of glutamate-induced [45Ca2+] uptake in synaptosomes in rat brain cortex at 0.5 uM after 5 mins by scintillation counting relative to control2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis, biological activity, distribution and membrane permeability of novel spiro-thiazines as potent neuroprotectors.
AID88594In vitro neuroprotection against glutamate-induced toxicity at 5 uM using rat hippocampal cell cultures at 30 uM of glutamate1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
10,5-(Iminomethano)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene and derivatives. Potent PCP receptor ligands.
AID143321Binding affinity at TCP site of NMDA receptor was determined in rat brain homogenate by [3H]TCP displacement.1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Discovery of 6,11-ethano-12,12-diaryl-6,11-dihydrobenzo[b]quinolizinium cations, a novel class of N-methyl-D-aspartate antagonists.
AID1415567Displacement of [3H]-ifenprodil from GluN2B receptor (unknown origin) expressed in mouse L (tk-) cell membranes after 120 mins by scintillation counting method2017MedChemComm, May-01, Volume: 8, Issue:5
Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?
AID376759Neuroprotective effect against glutamate-stimulated rat cortical cells assessed as cell viability at 0.1 uM after 1 hr by LDH assay relative to control2005Journal of natural products, Jan, Volume: 68, Issue:1
Four new neuroprotective dihydropyranocoumarins from Angelica gigas.
AID71570Tested for in vitro inhibition of the displacement of [3H]mazindol from GABA receptor1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and binding properties of MK-801 isothiocyanates; (+)-3-isothiocyanato-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten- 5,10-imine hydrochloride: a new, potent and selective electrophilic affinity ligand for the NMDA receptor-coupled phencycli
AID377500Effect on short term memory of CF1 mouse assessed as reduction in step down latency at 0.15 mg/kg by by passive avoidance test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID229181Tested for in vitro inhibition of the displacement of (+)-[3H]pentazocine from sigma opioid receptor1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and binding properties of MK-801 isothiocyanates; (+)-3-isothiocyanato-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten- 5,10-imine hydrochloride: a new, potent and selective electrophilic affinity ligand for the NMDA receptor-coupled phencycli
AID1129538Inhibition of glutamate-induced [45Ca2+] uptake in synaptosomes in rat brain cortex at 5 uM after 5 mins by scintillation counting relative to control2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis, biological activity, distribution and membrane permeability of novel spiro-thiazines as potent neuroprotectors.
AID480463Cytotoxicity against mouse L12-G10 cells by MTT assay2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID1597395Displacement of [3H] ifenprodil from GluN2B/GluN1a (unknown origin) expressed in mouse L(tk-) cell membranes incubated for 120 mins by scintillation counting method
AID604209Inhibition of nNOS in Sprague-Dawley rat brain homogenates assessed as conversion of oxyhemoglobin to methemoglobin measured for 10 mins by UV-visible spectrophotometer analysis2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
AID377497Effect on short term memory of CF1 mouse assessed as reduction in latency during aquisition at 0.15 mg/kg by by passive avoidance test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID1265114Binding affinity to rat brain NMDA receptor2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
A novel class of negative allosteric modulators of NMDA receptor function.
AID140979Tested for in vitro inhibition of the displacement of [3H]QNB from CNS receptor1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and binding properties of MK-801 isothiocyanates; (+)-3-isothiocyanato-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten- 5,10-imine hydrochloride: a new, potent and selective electrophilic affinity ligand for the NMDA receptor-coupled phencycli
AID142990Inhibition of N-methyl-D-aspartate glutamate receptor (NMDA receptor) from homogenized rat brain membrane, using [3H]-MK-801 as a radioligand1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and pharmacological evaluation of a series of dibenzo[a,d]cycloalkenimines as N-methyl-D-aspartate antagonists.
AID223455Evaluated in vivo for its NMDA antagonist activity by the inhibition of NMDA-induced lethality in mice1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
Synthesis and pharmacological evaluation of 4a-phenanthrenamine derivatives acting at the phencyclidine binding site of the N-methyl-D-aspartate receptor complex.
AID173063Percent change in reduction of photochemically induced cerebral focal ischemia in control and treated rat at 3 mg/kg intravenous dose1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis, resolution, and SAR of (+/-)-2-amino-N-methyl-alpha-(3-methyl-2-thienyl)benzeneethanamine++ + and related analogs as noncompetitive NMDA antagonists with neuroprotective properties.
AID1265113Neuroprotective activity in rat primary hippocampal neurons assessed as 100 uM NMDA and 30 uM glycine induced LDH release in media at 10 uM after 20 to 24 hrs by spectrophotometric analysis2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
A novel class of negative allosteric modulators of NMDA receptor function.
AID229187Inhibition of specific binding of [125I]PIPAG to sigma receptor in Guinea pig brain membranes1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Radiosynthesis, cerebral distribution, and binding of [125I]-1-(p-iodophenyl)-3-(1-adamantyl)guanidine, a ligand for sigma binding sites.
AID145237Tested for in vitro inhibition of the displacement of [3H]TCP from NMDA receptor1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and binding properties of MK-801 isothiocyanates; (+)-3-isothiocyanato-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten- 5,10-imine hydrochloride: a new, potent and selective electrophilic affinity ligand for the NMDA receptor-coupled phencycli
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID339209Antagonist activity at NR1/2B receptor expressed in xenopus laevis at pH 6.9 by two electrode voltage clamp method2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Theoretical studies on the structure and symmetry of the transmembrane region of glutamatergic GluR5 receptor.
AID191878Evaluated for reduction of NMDA-induced necrosis volume at 0.7 mg/kg intraperitoneally dose in rats.1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis, resolution, and SAR of (+/-)-2-amino-N-methyl-alpha-(3-methyl-2-thienyl)benzeneethanamine++ + and related analogs as noncompetitive NMDA antagonists with neuroprotective properties.
AID598086Antagonist activity at NR2A transfected in oocytes2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.
AID620266Antagonist activity at voltage gated calcium channel in Sprague-Dawley rat striatal synaptoneurosomes assessed as inhibition of NMDA/glycine-induced calcium flux at 100 uM by spectrofluorimetric analysis relative to control2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis, evaluation and application of polycyclic fluorescent analogues as N-methyl-D-aspartate receptor and voltage gated calcium channel ligands.
AID770308Anti-ischemic activity in Sprague-Dawley rat cortical neurons assessed as reduction of oxygen-glucose deprivation/reoxygenation-induced neuronal injury at 10 uM incubated for 30 mins prior to induction of oxygen-glucose deprivation and maintained during e2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
Discovery of novel (1S)-(-)-verbenone derivatives with anti-oxidant and anti-ischemic effects.
AID376760Neuroprotective effect against glutamate-stimulated rat cortical cells assessed as cell viability at 1 uM after 1 hr by LDH assay relative to control2005Journal of natural products, Jan, Volume: 68, Issue:1
Four new neuroprotective dihydropyranocoumarins from Angelica gigas.
AID770305Anti-excitotoxic activity in Sprague-Dawley rat cortical neurons assessed as reduction of NMDA-evoked neuronal injury at 10 uM incubated for 30 mins prior to NMDA induction and maintained during NMDA induction for 15 mins measured after 9 hrs2013Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19
Discovery of novel (1S)-(-)-verbenone derivatives with anti-oxidant and anti-ischemic effects.
AID143009Binding affinity against dextromethorpin binding site associated with N-methyl-D-aspartate glutamate receptor from guinea pig microsomal pellet P3 determined at a concentration of 10e-5 M using [3H]1 as radioligand.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and evaluation of 3-substituted 17-methylmorphinan analogs as potential anticonvulsant agents.
AID480459Inhibition of dexamethasone-induced human NR1-1a/NR2A receptor-mediated excitotoxicity in (S)-glutamate/glycine-stimulated mouse L12-G10 cells assessed as LDH release at 50 nM after 30 mins2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID19413LogD value of the compound1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Discovery of 6,11-ethano-12,12-diaryl-6,11-dihydrobenzo[b]quinolizinium cations, a novel class of N-methyl-D-aspartate antagonists.
AID144327Antagonism of N-methyl-D-aspartate glutamate receptor was measured as [Ca2+] influx in rat cerebellar granule neurons at 1 uM concentration1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Synthesis and biology of the conformationally restricted ACPD analogue, 2-aminobicyclo[2.1.1]hexane-2,5-dicarboxylic acid-I, a potent mGluR agonist.
AID1191391Displacement of [3H]MK801 from pig brain cortex NMDA receptor PCP binding site at 1 uM by scintillation analyzer2015European journal of medicinal chemistry, Jan-27, Volume: 90Improving selectivity preserving affinity: new piperidine-4-carboxamide derivatives as effective sigma-1-ligands.
AID298775Antinociceptive effect in po dosed mouse assessed as reduction of licking time in late phase by formalin test2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
Chiral tetrahydroquinoline derivatives as potent anti-hyperalgesic agents in animal models of sustained inflammation and chronic neuropathic pain.
AID480464Cytotoxicity against mouse L12-G10 cells at 50 uM by MTT assay2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID1597398Displacement of [3H]-di-o-tolylguanidine from sigma2 receptor in rat liver membranes incubated for 120 mins by scintillation counting method
AID144702Inhibitory activity against NMDA open channel block1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel benzo[b]quinolizinium cations as uncompetitive N-methyl-D-aspartic acid (NMDA) antagonists: the relationship between log D and agonist independent (closed) NMDA channel block.
AID19422logD value was determined1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel benzo[b]quinolizinium cations as uncompetitive N-methyl-D-aspartic acid (NMDA) antagonists: the relationship between log D and agonist independent (closed) NMDA channel block.
AID225475Ability to inhibit glutamate induced accumulation of [45 [Ca2+]] in cultured rat cortical neurons1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
Synthesis and pharmacological evaluation of 4a-phenanthrenamine derivatives acting at the phencyclidine binding site of the N-methyl-D-aspartate receptor complex.
AID1672597Displacement of [3H]-(+)-MK-801 from PCP binding site of NMDA receptor in pig brain cortex membranes after 120 mins by scintillation counting analysis2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Role of the NMDA Receptor in the Antitumor Activity of Chiral 1,4-Dioxane Ligands in MCF-7 and SKBR3 Breast Cancer Cells.
AID1129539Inhibition of glutamate-induced [45Ca2+] uptake in synaptosomes in rat brain cortex at 1 uM after 5 mins by scintillation counting relative to control2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis, biological activity, distribution and membrane permeability of novel spiro-thiazines as potent neuroprotectors.
AID255298Percent inhibition against Muscarinic acetylcholine receptor M5 at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID222489Testing for ataxia was done by using an inverted screen technique1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
Synthesis and pharmacological evaluation of 4a-phenanthrenamine derivatives acting at the phencyclidine binding site of the N-methyl-D-aspartate receptor complex.
AID156963Potency for binding towards PCP receptor relative to that of phencyclidine1998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
Rigid phencyclidine analogues. Binding to the phencyclidine and sigma 1 receptors.
AID1672601Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Role of the NMDA Receptor in the Antitumor Activity of Chiral 1,4-Dioxane Ligands in MCF-7 and SKBR3 Breast Cancer Cells.
AID1597397Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain cortex membranes incubated for 120 mins by scintillation counting method
AID145330In vitro binding to N-methyl-D-aspartate glutamate receptor using [3H]MK-801 (1 nM) and rat brain membrane suspensions2002Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12
Synthesis and in vitro evaluation of N,N'-diphenyl and N-naphthyl-N'-phenylguanidines as N-methyl-D-aspartate receptor ion-channel ligands.
AID145039The compound was tested in vitro for the displacement of the radioligand (+)-[3H]-MK-801 from synaptic plasma membranes from rat cortex against N-methyl-D-aspartate glutamate receptor2000Bioorganic & medicinal chemistry letters, Nov-06, Volume: 10, Issue:21
Chiral synthesis and pharmacological evaluation of NPS 1407: a potent, stereoselective NMDA receptor antagonist.
AID377505Effect on long term memory of CF1 mouse assessed as reduction in latency during aquisition at 0.15 mg/kg by by passive avoidance test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID1415571Displacement of [3H](+)-Pentazocine from sigma 1 receptor in guinea pig brain membranes after 120 mins by scintillation counting analysis2017MedChemComm, May-01, Volume: 8, Issue:5
Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?
AID1441555Displacement of [3H]-(+)-MK 801 from PCP binding site of NMDA receptor in pig brain cortex membranes after 120 mins by solid scintillation counting2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Design and Synthesis of Enantiomerically Pure Decahydroquinoxalines as Potent and Selective κ-Opioid Receptor Agonists with Anti-Inflammatory Activity in Vivo.
AID305668Antagonist activity at NMDA receptor in ICR mouse synaptoneurosome assessed as inhibition of NMDA/Gly-mediated 45-calcium influx2007Bioorganic & medicinal chemistry, Feb-01, Volume: 15, Issue:3
Structure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID144832Binding affinity towards PCP site of the NMDA receptor was measured by displacement of [3H]TPC in whole rat brain homogenate1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
Synthesis and pharmacological evaluation of 4a-phenanthrenamine derivatives acting at the phencyclidine binding site of the N-methyl-D-aspartate receptor complex.
AID144979Potency towards NMDA receptor measured as inhibition of (+)-[3-3H]MK-801 binding from synaptic plasma membrane obtained from rat cortex1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Synthesis, biological activity, and absolute stereochemical assignment of NPS 1392: a potent and stereoselective NMDA receptor antagonist.
AID1285650Displacement of [3H]TCP from rat cerebral cortex PCP receptor2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
AID139967Neuroprotection was determined against NMDA induced cell death in cultured mouse cortical neuron.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Novel NMDA antagonists: replacement of the pyridinium ring of 6,11-ethanobenzo[b]quinolizinium cations with heteroisoquinolinium cations.
AID188226Evaluated for reduction of NMDA-induced necrosis at 2.0 mg/kg intraperitoneal dose in rats.1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis, resolution, and SAR of (+/-)-2-amino-N-methyl-alpha-(3-methyl-2-thienyl)benzeneethanamine++ + and related analogs as noncompetitive NMDA antagonists with neuroprotective properties.
AID156835Inhibition of [3H]-TCP binding to PCP receptor obtained from tissue homogenate preparation of fresh whole rat brain minus cerebellum1998Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4
Rigid phencyclidine analogues. Binding to the phencyclidine and sigma 1 receptors.
AID179046Compound was evaluated for the inhibition of glutamate-stimulated calcium influx (GSCI)1993Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6
Synthesis and pharmacological evaluation of hexahydrofluorenamines as noncompetitive antagonists at the N-methyl-D-aspartate receptor.
AID156805The compound was tested for its ability to block PCP N-methyl-D-aspartate glutamate receptor at the PCP (phencyclidine) binding site in postmortem human frontal cortex.1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site.
AID144038Binding affinity against glycine binding site associated with N-methyl-D-aspartate glutamate receptor from rat synaptic plasma membrane(SPM) determined at a concentration of 10e-5 M using [3H]glycine as radioligand.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and evaluation of 3-substituted 17-methylmorphinan analogs as potential anticonvulsant agents.
AID88595In vitro neuroprotection against glutamate-induced toxicity at 5 uM using rat hippocampal cell cultures at 300 uM of glutamate1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
10,5-(Iminomethano)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene and derivatives. Potent PCP receptor ligands.
AID144970Inhibition against NMDA receptor by displacement of [3H]TCP binding from rat cortical membranes1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis, resolution, and SAR of (+/-)-2-amino-N-methyl-alpha-(3-methyl-2-thienyl)benzeneethanamine++ + and related analogs as noncompetitive NMDA antagonists with neuroprotective properties.
AID231442Ratio (closed/open) was determined1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel benzo[b]quinolizinium cations as uncompetitive N-methyl-D-aspartic acid (NMDA) antagonists: the relationship between log D and agonist independent (closed) NMDA channel block.
AID1129537Inhibition of glutamate-induced [45Ca2+] uptake in synaptosomes in rat brain cortex at 10 uM after 5 mins by scintillation counting relative to control2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis, biological activity, distribution and membrane permeability of novel spiro-thiazines as potent neuroprotectors.
AID1415568Displacement of [3H]-(+)-MK-801 from PCP binding site of NMDA receptor in pig brain cortex membranes after 90 mins by scintillation counting method2017MedChemComm, May-01, Volume: 8, Issue:5
Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?
AID139968Inhibitory concentration against NMDA-induced cell death in cultured mouse cortical neurons1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
Discovery of 6,11-ethano-12,12-diaryl-6,11-dihydrobenzo[b]quinolizinium cations, a novel class of N-methyl-D-aspartate antagonists.
AID253096Effect on total cerebral infarct volume measured 24 hour after permanent MCA occlusion in rat at a dose of 3 mg/kg (n=6)2005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
Novel alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor antagonists of 2,3-benzodiazepine type: chemical synthesis, in vitro characterization, and in vivo prevention of acute neurodegeneration.
AID156824Inhibition of [3H]MK-801 binding to the PCP receptor site in guinea pig brain homogenate1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
10,5-(Iminomethano)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene and derivatives. Potent PCP receptor ligands.
AID1191390Selectivity ratio of Ki for rat liver sigma2 receptor to Ki for guinea pig brain cortex sigma1 receptor2015European journal of medicinal chemistry, Jan-27, Volume: 90Improving selectivity preserving affinity: new piperidine-4-carboxamide derivatives as effective sigma-1-ligands.
AID229193Inhibition of specific binding of [3H]NANM of sigma receptor in Guinea pig brain membranes1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Radiosynthesis, cerebral distribution, and binding of [125I]-1-(p-iodophenyl)-3-(1-adamantyl)guanidine, a ligand for sigma binding sites.
AID1456403Displacement of [3H]-(+)-MK-801 from NMDA PCP binding site in pig brain cortex membrane incubated for 120 mins measured for 5 mins by scintillation counting method
AID71569In vitro inhibition of [3H]flunitrazepam displacement from GABA-A receptor1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and binding properties of MK-801 isothiocyanates; (+)-3-isothiocyanato-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten- 5,10-imine hydrochloride: a new, potent and selective electrophilic affinity ligand for the NMDA receptor-coupled phencycli
AID88589In vitro neuroprotection against glutamate-induced toxicity at 5 uM using rat hippocampal cell cultures at 0 uM of glutamate1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
10,5-(Iminomethano)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene and derivatives. Potent PCP receptor ligands.
AID144471Binding affinity against PCP binding site associated with N-methyl-D-aspartate glutamate receptor from rat synaptic plasma membrane(SPM) determined using [3H]TCP as radioligand.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and evaluation of 3-substituted 17-methylmorphinan analogs as potential anticonvulsant agents.
AID114708Effective dose required for 50% inhibition of clonic seizures in mice induced by racemic NMDLA when administered intraperitoneally1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis, resolution, and SAR of (+/-)-2-amino-N-methyl-alpha-(3-methyl-2-thienyl)benzeneethanamine++ + and related analogs as noncompetitive NMDA antagonists with neuroprotective properties.
AID378493Effect on long term memory of CF1 mouse assessed as reduction in step down latency at 0.15 mg/kg by by passive avoidance test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID204608Inhibition of [3H]- N-allylnormetazocine ([3H]NANM) binding to sigma receptor1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Phencyclidine-like effects of tetrahydroisoquinolines and related compounds.
AID1129535Inhibition of glutamate-induced [45Ca2+] uptake in synaptosomes in rat brain cortex at 50 uM after 5 mins by scintillation counting relative to control2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis, biological activity, distribution and membrane permeability of novel spiro-thiazines as potent neuroprotectors.
AID145318Displacement of [3H]TCP from NMDA receptor of rat brain membranes1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists.
AID75120Percent reduction of carotid artery Carotid artery occlusion-induced hippocampal damage at 5 mg/kg intraperitoneal dose.1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis, resolution, and SAR of (+/-)-2-amino-N-methyl-alpha-(3-methyl-2-thienyl)benzeneethanamine++ + and related analogs as noncompetitive NMDA antagonists with neuroprotective properties.
AID143323Percentage inhibition of N-methyl-D-aspartic acid (NMDA) receptor produced by oocytes1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxami de, an efficient noncompetitive N-methyl-D-aspartic acid receptor antagonist.
AID145236Tested for in vitro inhibition of the displacement of (+)-[3H]dizocilpine from NMDA receptor1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and binding properties of MK-801 isothiocyanates; (+)-3-isothiocyanato-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten- 5,10-imine hydrochloride: a new, potent and selective electrophilic affinity ligand for the NMDA receptor-coupled phencycli
AID144969Functional NMDA receptor antagonism expressed as inhibition of NMDA/glycine induced increase in cytosolic calcium in cultured rat cerebellar granule cells1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Synthesis, biological activity, and absolute stereochemical assignment of NPS 1392: a potent and stereoselective NMDA receptor antagonist.
AID179985Tested for the protection against glutamic acid-evoked convulsions in rats by intraperitoneal administration1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Riluzole series. Synthesis and in vivo "antiglutamate" activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines.
AID188224Evaluated for reduction of NMDA-induced necrosis at 0.7 mg/kg intraperitoneal dose in rats.1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis, resolution, and SAR of (+/-)-2-amino-N-methyl-alpha-(3-methyl-2-thienyl)benzeneethanamine++ + and related analogs as noncompetitive NMDA antagonists with neuroprotective properties.
AID75245Carotid artery occlusion-induced hippocampal damage was evaluated by using compound 15 min before carotid occlusion at 5 mg/kg intraperitoneal dose.1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis, resolution, and SAR of (+/-)-2-amino-N-methyl-alpha-(3-methyl-2-thienyl)benzeneethanamine++ + and related analogs as noncompetitive NMDA antagonists with neuroprotective properties.
AID74939Carotid artery occlusion-induced hippocampal damage was evaluated by using control 15 min before carotid occlusion at 5 mg/kg intraperitoneal dose.1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis, resolution, and SAR of (+/-)-2-amino-N-methyl-alpha-(3-methyl-2-thienyl)benzeneethanamine++ + and related analogs as noncompetitive NMDA antagonists with neuroprotective properties.
AID1300696Analgesic activity in Wistar rat assessed as inhibition of NMDA-induced pain at 0.1 ug, it administered 30 mins prior to NMDA challenge measured for 10 mins2016European journal of medicinal chemistry, Jul-19, Volume: 117Discovery and analgesic evaluation of 8-chloro-1,4-dihydropyrido[2,3-b]pyrazine-2,3-dione as a novel potent d-amino acid oxidase inhibitor.
AID92041Percent control measured by evaluating the inhibition of 3 nM [125I]PhTX-343-lysine binding to glutamate receptors in rat cortical membranes1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and binding of [125I2]philanthotoxin-343, [125I2]philanthotoxin-343-lysine, and [125I2]philanthotoxin-343-arginine to rat brain membranes.
AID481109Displacement of [3H]MK801 from NMDA receptor phencyclidine binding site2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Conformationally constrained kappa receptor agonists: stereoselective synthesis and pharmacological evaluation of 6,8-diazabicyclo[3.2.2]nonane derivatives.
AID224709Tested for in vitro inhibition of the displacement of [3H]FOXY from mu opioid receptor1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis and binding properties of MK-801 isothiocyanates; (+)-3-isothiocyanato-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten- 5,10-imine hydrochloride: a new, potent and selective electrophilic affinity ligand for the NMDA receptor-coupled phencycli
AID188228Evaluated for reduction of NMDA-induced necrosis at 7.0 mg/kg intraperitoneal dose in rats.1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Synthesis, resolution, and SAR of (+/-)-2-amino-N-methyl-alpha-(3-methyl-2-thienyl)benzeneethanamine++ + and related analogs as noncompetitive NMDA antagonists with neuroprotective properties.
AID1693240Neuroprotective activity in Sprague-Dawley rat cortical neurons assessed as reduction in glutamate-induced cell death preincubated for 1 hr followed by glutamate stimulation and measured after 24 hrs by MTS assay2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 32Synthesis, biological evaluation, and NMR studies of 3-fluorinated derivatives of 3',4',5'-trihydroxyflavone and 3',4',5'-trimethoxyflavone.
AID143010Binding affinity against dextromethorpin binding site associated with N-methyl-D-aspartate glutamate receptor from rat brain determined at a concentration of 10e-5 M using [3H]1 as radioligand.1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and evaluation of 3-substituted 17-methylmorphinan analogs as potential anticonvulsant agents.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID157589Inhibition of [3H]1-[1-(2-thienyl) piperidine ([3H]TCP) binding to phencyclidine receptor1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Phencyclidine-like effects of tetrahydroisoquinolines and related compounds.
AID145329In vitro radioligand binding assay for the N-methyl-D-aspartate glutamate receptor is performed using [3H]MK-801 and rat brain membrane suspensions1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Synthesis and pharmacological evaluation of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methylguanidines as N-methyl-D-aspartate receptor ion-channel blockers.
AID1346501Mouse Kir3.2 (Inwardly rectifying potassium channels)1996Neuron, May, Volume: 16, Issue:5
Functional analysis of the weaver mutant GIRK2 K+ channel and rescue of weaver granule cells.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (77)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.30)18.7374
1990's24 (31.17)18.2507
2000's15 (19.48)29.6817
2010's26 (33.77)24.3611
2020's11 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.60%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other75 (97.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]